• Synageva BioPharma Corp., of Lexington, Mass., reported results from a four-week Phase I/II study of enzyme replacement candidate SBC-102 in adults with late onset lysosomal acid lipase (LAL) deficiency, showing the drug was well tolerated, with no serious adverse events or infusion-related reactions.